Health Care
Commentary
How much does your health care cost? Trump wants you to know and save money
President Trump recently signed an executive order that aims to force hospitals, doctors, and insurers to be more transparent about their prices. Currently, those prices are negotiated and set in secret. Consumers have no idea what their care will cost and so are unable to shop around for the best ...
Commentary
Cost-Saving Biosimilars’ Many Obstacles
Innovating new drugs is an expensive and uncertain business, typically taking 10-12 years and costing, on average, $2.55 billion to bring a new product to market. The risks are enormous, and deserve significant financial rewards; at the same time, it’s undeniable that the costs of many new, complex drugs are ...
Health Care
Read Heartland News Story on Sally Pipes Creation of Benjamin Rush Institute
Organization Spreads Pro-Freedom Ideas in Medical Schools By Leo Pusateri In a time when 51 percent of millennials say they have a positive view of socialism, there is an organization spreading the word of free markets and capitalism in one of the sectors most vulnerable to government command and control: ...
Commentary
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Blog
Despite High Costs, Americans Support Potential of Innovative Gene Therapies to Cure Difficult-to-Treat Diseases
SAN FRANCISCO – A new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI), shows that Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses. Click here to read the top-line results of PRI’s poll on gene therapies ...
Blog
Celebrating 100 Episodes of “Next Round with PRI”
This week marks a milestone for PRI’s weekly “Next Round” podcast as we celebrate our 100th episode. When we first started the podcast in July 2017, our podcast had a different name, “Another Round with PRI” (I won’t go into the story of why we changed our name). Sally Pipes’ ...
Commentary
‘Medicare for All’ Is A Trap for Businesses and Employees
Some business leaders are hopping aboard the Medicare for All bandwagon. The Business Alliance for a Healthy California, for example, now has 300 businesses calling for universal healthcare. But any businessman considering getting behind Medicare for All should know the sales pitch is flawed. The architects of Medicare for All ...
Commentary
Democrats don’t understand ‘Medicare-for-all’
Next week, 20 Democratic presidential hopefuls will gather in Miami for their first debate. One issue is sure to dominate the discussion – “Medicare-for-all.” The promise of free, government-run health care has become quite popular among Democrats since Sen. Bernie Sanders, I-Vt., made it a major plank of his 2016 ...
Commentary
Medicaid expansion is a failure: Lots of spending, little benefit
Researchers from MIT and Harvard recently released a report concluding that Obamacare had a “clearly positive effect on access to and consumption of health care.” Nearly 16 million people gained coverage through Medicaid expansion while just over 11 million purchased insurance through Obamacare’s exchanges in the past year. But that ...
Commentary
We Need Reciprocity Of Drug Approvals To Address Critical Drug Shortages
By Henry I. Miller and John J. Cohrssen Published in Issues and Insights We hear a lot about rising drug prices, but largely ignored is a far more acute and worrisome problem: widespread shortages of critical medications, many of which are essential in medical practice. University of Chicago researchers last ...
How much does your health care cost? Trump wants you to know and save money
President Trump recently signed an executive order that aims to force hospitals, doctors, and insurers to be more transparent about their prices. Currently, those prices are negotiated and set in secret. Consumers have no idea what their care will cost and so are unable to shop around for the best ...
Cost-Saving Biosimilars’ Many Obstacles
Innovating new drugs is an expensive and uncertain business, typically taking 10-12 years and costing, on average, $2.55 billion to bring a new product to market. The risks are enormous, and deserve significant financial rewards; at the same time, it’s undeniable that the costs of many new, complex drugs are ...
Read Heartland News Story on Sally Pipes Creation of Benjamin Rush Institute
Organization Spreads Pro-Freedom Ideas in Medical Schools By Leo Pusateri In a time when 51 percent of millennials say they have a positive view of socialism, there is an organization spreading the word of free markets and capitalism in one of the sectors most vulnerable to government command and control: ...
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Despite High Costs, Americans Support Potential of Innovative Gene Therapies to Cure Difficult-to-Treat Diseases
SAN FRANCISCO – A new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI), shows that Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses. Click here to read the top-line results of PRI’s poll on gene therapies ...
Celebrating 100 Episodes of “Next Round with PRI”
This week marks a milestone for PRI’s weekly “Next Round” podcast as we celebrate our 100th episode. When we first started the podcast in July 2017, our podcast had a different name, “Another Round with PRI” (I won’t go into the story of why we changed our name). Sally Pipes’ ...
‘Medicare for All’ Is A Trap for Businesses and Employees
Some business leaders are hopping aboard the Medicare for All bandwagon. The Business Alliance for a Healthy California, for example, now has 300 businesses calling for universal healthcare. But any businessman considering getting behind Medicare for All should know the sales pitch is flawed. The architects of Medicare for All ...
Democrats don’t understand ‘Medicare-for-all’
Next week, 20 Democratic presidential hopefuls will gather in Miami for their first debate. One issue is sure to dominate the discussion – “Medicare-for-all.” The promise of free, government-run health care has become quite popular among Democrats since Sen. Bernie Sanders, I-Vt., made it a major plank of his 2016 ...
Medicaid expansion is a failure: Lots of spending, little benefit
Researchers from MIT and Harvard recently released a report concluding that Obamacare had a “clearly positive effect on access to and consumption of health care.” Nearly 16 million people gained coverage through Medicaid expansion while just over 11 million purchased insurance through Obamacare’s exchanges in the past year. But that ...
We Need Reciprocity Of Drug Approvals To Address Critical Drug Shortages
By Henry I. Miller and John J. Cohrssen Published in Issues and Insights We hear a lot about rising drug prices, but largely ignored is a far more acute and worrisome problem: widespread shortages of critical medications, many of which are essential in medical practice. University of Chicago researchers last ...
